J&J Buying Stroke-Treatment Co Micrus For $480M

Johnson & Johnson (JNJ) said Monday it plans to bolster its lineup of stroke-prevention products by buying Micrus Endovascular Corp. (MEND) for about $480 million, marking the latest deal in a neurovascular-device market that appears to be heating up.

J&J's planned purchase of San Jose, Calif.-based Micrus comes weeks after rival Covidien PLC (COV) announced plans to buy ev3 Corp. (EVVV), a Micrus rival, for $2.6 billion. Leerink Swann analyst Rick Wise said the Covidien-ev3 combination may have spurred on J&J due to a hospital-purchasing trend of focusing more on ...

Read More Here

Posted By

Josh Sandberg has been recruiting specifically in the musculoskeletal industry for over 8 years. Throughout this time, he has been able to have a positive impact on his client’s businesses. With an educational background in Business Management, Josh is adept to discern which people will be the best fit for the company he is searching for by understanding how candidates will incorporate with the company’s culture and operational nuances. His experience as an executive in a start-up business has granted him the ability to understand what is takes to thrive in a hands–on environment, where desire and dedication are paramount for success.